The International AIDS Society HIV Research for Prevention (HIVR4P) presented positive results on their HIV studies at a virtual conference in the beginning of 2021. Clinical trials on a developing HIV vaccine were carried out in order to test the effectiveness of the vaccine. The vaccine successfully produced rare immune cells that are needed in the generation of antibodies that protect the body from the virus.

A professor and immunologist at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center, whose laboratory developed the vaccine, Wiliam Schief, PHD, shared the following remarks:

“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well. With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens.”

These successful test results have now laid the foundation for more clinical tests to be carried out on the vaccine.The additional tests are aimed at ensuring that the vaccine is refined and to extend the approach of the long-term goal of creating a safe and effective HIV vaccine.

Julie McElrath, MD, PhD, senior vice president and director of Fred Hutch’s Vaccine and Infectious Disease Division confidently referred to this achievement as a “landmark” in the research being carried out on HIV vaccines and vaccines in general. She highlighted that this was indeed a huge step in the development of neutralising antibodies against HIV-1. It is anticipated this success will inevitably accelerate the progress of the HIV-vaccine creation.

What are your thoughts on these findings?

Let us know in the comment section below.

The post HIV vaccine on its way after successful trials appeared first on Provoker Magazine.